Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 31 Mar 2025 |
| TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer | 31 Mar 2025 |
| TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy | 27 Mar 2025 |
| Genmab Announces Initiation of Share Buy-Back Program | 25 Mar 2025 |
| Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. | 22 Mar 2025 |